Intrinsiqq
Exact Sciences Corp logo

Exact Sciences Corp Financials

EXAS

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 17 available years
Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$3,247$2,759$2,500$2,084$1,767
Cost of Revenue$984$840$738$661$459
Gross Profit$2,263$1,919$1,762$1,423$1,308
Operating Expenses
Selling & Marketing$1,050$894$828$930$862
General & Administrative$889$782$800$663$801
Research & Development$523$431$427$394$386
Other Operating Expenses$0$9$78-$13$0
Total Operating Expenses$2,469$2,977$2,056$2,003$2,623
Operating Income-$206-$1,049-$215-$594-$856
Non-Operating
Net Interest Expense-$39-$27-$19-$20$13
Other Non-Operating Income (Expense)$42$40$33-$19$0
EBT (Earnings Before Tax)-$204-$1,036-$202-$633-$843
Income Tax Expense$4-$7$2-$9-$247
Net Income
Net Income-$208-$1,029-$204-$624-$596
Per Share Data
Revenue Per Share$17.21$14.98$13.88$11.82$10.31
EPS (Basic)-$1.10-$5.59-$1.13-$3.54-$3.48
EPS (Diluted)-$1.10-$5.59-$1.13-$3.54-$3.48
Weighted Avg Shares (Basic)188.7M184.2M180.1M176.4M171.3M
Weighted Avg Shares (Diluted)188.7M184.2M180.1M176.4M171.3M
Shares Outstanding188.7M184.2M180.1M176.4M171.3M

Exact Sciences (EXAS) financials: revenue, profit and margins

Exact Sciences (EXAS) generated about $3.2 billion in revenue and -$208 million in net income (a -6.4% net margin) over the trailing twelve months, growing at roughly 16.8% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Exact Sciences's (EXAS) revenue?+

Exact Sciences generated about $3.2 billion in revenue over the trailing twelve months. Revenue has grown at roughly 16.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Exact Sciences profitable?+

Exact Sciences reported about -$208 million in net loss over the trailing twelve months, a net margin of roughly -6.4%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Exact Sciences's profit margins?+

Exact Sciences runs a gross margin of about 69.7%, an operating margin of about -6.4%, a net margin of about -6.4%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Exact Sciences growing?+

Exact Sciences's revenue has compounded at roughly 16.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside EXAS's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 12 Feb 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Services-Medical Laboratories · Pick stocks to compare with EXAS

CompareIntrinsic value
NTRANATERA INC (Common Stock) – ticker 45E
$391.03+0.62%61
FTREFortrea Holdings Inc.
$20.74-1.00%29
RDNTRadNet Inc.
$80.26+9.67%39
GHGuardant Health Inc.
$168.58-3.67%30
CAICaris Life Sciences, Inc.
$32.31-1.66%71
VCYTVeracyte Inc.
$52.52+4.43%68
CDNACareDx Inc.
$85.86-2.95%57
BLLNBillionToOne, Inc.
$113.89+3.11%63

Held by ETFs

EXAS is in 1 US ETF. The largest of them, with EXAS's weight in each:

Spot a number that looks wrong? Check it in EXAS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EXAS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.